- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02774239
A Pilot Trial To Assess The Feasibility And Efficacy Of SCIG In Patients With MG Exacerbation (SCIG-MG) (SCIG-MG)
A Pilot Trial To Assess The Feasibility And Efficacy Of Subcutaneous Immunoglobulin In Patients With Myasthenia Gravis Exacerbation
This is a prospective open-label, uncontrolled, single-blind, pilot clinical trial.
The primary objective is to assess the efficacy, safety, feasibility and tolerability of SCIG in patients with worsening MG.
Participants with moderate worsening of MG symptoms (MGFA Class II and III) who are considered to be appropriate for immunoglobulin therapy will be screened for the study by the treating neurologist.
Patients will be receive 2gm/kg (150gm for a 75kg patient) of 20% SCIG (Hizentra) infused over 4 weeks in a dose escalating manner.
Additionally, this study will be assessing the feasibility of employing SCIG as an alternative therapy to IVIG in patients with MG exacerbation. The cost-effectiveness of SCIG versus IVIG will be evaluated, and the impact of SCIG therapy will be assessed from both a health-resource perspective and from a patient perspective.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a prospective open-label, uncontrolled, single-blind, pilot clinical trial.
The primary objective is to assess the efficacy, safety, feasibility and tolerability of SCIG in patients with worsening MG.
Study Rationale and Significance
Subcutaneous immunoglobulin (SCIG) is a novel form of immune therapy for neuromuscular diseases and may offer several advantages over intravenous immunoglobulin (IVIG).
Although no large-scale studies have been in conducted in MG patients, pilot studies with SCIG in multifocal motor neuropathy indicate that it may be a feasible, effective and safe alternative to IVIG in a condition, which like MG, shows excellent response to IVIG infusion.
Patients are able to tolerate it better and have improved quality of life due to added flexibility to the treatment schedule. SCIG is also potentially less expensive than IVIG since the costs associated with inpatient treatment as well as nursing support are saved.
SCIG also has the potential to be more effective and durable since the serum levels of immunoglobulin show a more sustained increase compared to IVIG. A drawback associated with SCIG is the small amount of immunoglobulin that can be infused over a short period. As compared to IVIG where the usual dose (2gm/kg for neuromuscular diseases) can be infused over 2 - 5 days, the same dose of SCIG would require 3 - 4 weeks to be administered with the currently available formulations. This may mean a delayed onset of peak-dose effect and SCIG may not be feasible for MG patients who are rapidly worsening or in MG crisis.
Nevertheless, SCIG may be an attractive option in a large subpopulation of MG patients who have mild to moderate disease exacerbations or who are on maintenance IVIG therapy provided its efficacy, tolerability and feasibility is determined in this patient population.
Methodology
Participants with moderate worsening of MG symptoms (MGFA Class II and III) who are considered to be appropriate for immunoglobulin therapy at the MG clinic at the University of Alberta will be screened for the study by the treating neurologist.
Patients will be receive 2gm/kg (150gm for a 75kg patient) of 20% SCIG (Hizentra) infused over 4 weeks in a dose escalating manner. Participants will undergo infusions two to four times a week, depending on their tolerance, beginning with a dose of 10 ml per site at four injection sites, increasing by 5 ml per week for a total of 25 ml per site at four injection sites after four weeks.
The dose is flexible and will vary based on the patient's tolerance to the medication and the total amount of medication the patient will be receiving based on their body weight. The initial (one or two) doses will be infused within the medical outpatient facility at the University of Alberta Hospital. This will allow for the observation of any infusion reactions and will also serve as nurse-provided self- infusion training sessions for patients.
Participants will be assessed weekly for symptomatic change and reports of satisfaction and quality of life. The primary outcome variable is the change in the Quantitative Myasthenia Gravis (QMG) Score for Disease Severity from baseline to day 42 (6 weeks). A change of 3.5 points will be considered to be clinically significant.
Safety and pharmacokinetic assessments of SCIG will be performed weekly throughout the study.
Additionally, this study will be assessing the feasibility of employing SCIG as an alternative therapy to IVIG in patients with MG exacerbation. The cost-effectiveness of SCIG versus IVIG will be evaluated, and the impact of SCIG therapy will be assessed from both a health-resource perspective and from a patient perspective.
The practicality of using SCIG in patients with MG will be determined by documenting the number of patients who are able to be trained for self- administration of SCIG, and by the patients' self-reported satisfaction with SCIG treatment.
The speed of SCIG treatment onset will also be assessed and compared to IVIG treatment onset. All of these described measures will be used to determine the feasibility and practicality of using SCIG in patients with MG exacerbation and its impact on the healthcare system.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Derrick G Blackmore, B.Sc
- Phone Number: 780-407-3367
- Email: dblackmo@ualberta.ca
Study Contact Backup
- Name: Ashley K Mallon, LPN
- Phone Number: 780-407-6582
- Email: akmallon@ualberta.ca
Study Locations
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 2B7
- University of Alberta
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 1M9
- Vancouver General Hospital - Gordon & Leslie Diamond Health Care Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients between18 to 80 years of age, diagnosed with MG (see below) who have worsening myasthenic symptoms - (defined as increasing diplopia, ptosis, dysarthria, dysphagia, difficulty chewing, or limb weakness severe enough to warrant immunoglobulin therapy.
MG diagnosis will be based upon the clinical evaluation by a neuromuscular expert and meeting any two of the following supportive criteria:
- Abnormal Tensilon test
- Abnormal repetitive nerve stimulation studies
- Abnormal single fiber electromyography (EMG)
- Increased serum acetylcholine receptor or anti-MuSK antibodies
- Prior response to immunotherapy
Exclusion Criteria:
- Respiratory distress requiring ICU admission or a vital capacity <1 L
- Severe swallowing difficulties with a high risk of aspiration
- Change in corticosteroid dosage in the 4 weeks prior to screening
- Known immunoglobulin A (IgA) deficiency
- Pregnant or breast feeding women
- Active renal or hepatic insufficiency, clinically significant cardiac disease
- Patients with worsening weakness associated with an infectious process
- Previous lack of responsiveness to IVIG
- History of previous MG crises
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SC Treatment Period
Participants will receive 2gm/kg of Human normal immunoglobulin G (IgG) infused over 4 weeks in a dose escalating manner as follows:
|
Study medication is available in the following forms: 5 mL (1 g IgG) in a 5 mL infusion bottle, 10 mL (2 g IgG) in a 10 mL infusion bottle, 20 mL (4 g IgG) in a 20 mL infusion bottle, 50 mL (10 g IgG) in a 50 mL infusion bottle. Patients will be receiving 2gm/kg (150gm for a 75kg patient) of 20% SCIG (Hizentra) infused over four weeks in a dose escalating manner.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Quantitative Myasthenia Gravis Score (QMGS) from baseline to day 42 after treatment.
Time Frame: Baseline - Day 42
|
QMGS is a validated clinical measure of myasthenia gravis ranging from 0 points (no myasthenic weakness) to a maximum of 39 points, with a defined change of 3.4 units required for clinical significance.
|
Baseline - Day 42
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quality of life will be assessed through the Quality of Life (QOL) score, a qualitative questionnaire.
Time Frame: Baseline - Day 42
|
Baseline - Day 42
|
|
Change in Manual Muscle Testing (MMT) score from baseline to day 42 after treatment.
Time Frame: Baseline - Day 42
|
MMT is a validated clinical measure of myasthenia gravis ranging from 0 points (no myasthenic weakness) to a maximum of 128 points, with a defined change of 25% from baseline required for clinical significance.
|
Baseline - Day 42
|
Adverse events related to SCIG infusions will be recorded if/when they occur.
Time Frame: Baseline - Day 42
|
Baseline - Day 42
|
|
Patient satisfaction with the treatment modality will be assessed using a questionnaire.
Time Frame: Day 42
|
TQSM: Treatment Satisfaction Questionnaire for Medication.
An 11 question ordinal scale measuring responses from "Extremely satisfied" to "Extremely dissatisfied" over a 7 item option list.
Questions cover four domains, corresponding to distinct aspects related to the satisfaction of patients with their treatment (Effectiveness; Side effects; Convenience and Global satisfaction).
A score can be obtained for each domain by summing of the corresponding items transformed on a 0-100 scale; higher values indicate higher satisfaction, better perceived effectiveness, lower burden associated to side-effects, better convenience
|
Day 42
|
Serious Adverse Events related to SCIG infusions will be recorded if/when they occur.
Time Frame: Baseline - Day 42
|
Baseline - Day 42
|
|
Proportion of participants successfully trained will be recorded indicating feasibility based on patient compliance.
Time Frame: Baseline - Week 2
|
Baseline - Week 2
|
|
Proportion of participants completing will be recorded indicating feasibility based on patient compliance.
Time Frame: Baseline - Day 42
|
Baseline - Day 42
|
|
Myasthenia Gravis (MG) Composite scores will be used to evaluate disease severity through a number of functional assessments, including muscle strength and ability to complete activities of daily living.
Time Frame: Baseline - Day 42
|
Baseline - Day 42
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cost effectiveness of SCIG therapy will be calculated in comparison to standard IVIG therapy. This will indicate health economics.
Time Frame: Baseline - Day 42
|
Baseline - Day 42
|
|
Change in QOL 36 score from Baseline to day 42)
Time Frame: Baseline - Day 42
|
Change in Quality of Life (QOL) score from Baseline to day 42.
|
Baseline - Day 42
|
Time required for the treatments.
Time Frame: Baseline - Day 42
|
Average time in minutes required for each infusion session during study.
Determined for each participant.
|
Baseline - Day 42
|
Preference for treatments (Treatment Satisfaction Questionnaire for Medication (TSQM).
Time Frame: Day 42
|
11 item scale measuring treatment satisfaction for medication over 3 domains (Effectiveness, Side effects, Convenience, Global Satisfaction).
Score from 10 to 43
|
Day 42
|
Intent to continue using SCIG if necessary (Via pt. interview)
Time Frame: Day 42
|
Yes= will continue SCIG therapy, No= will not continue SCIG therapy.
|
Day 42
|
Proportion of participants successfully trained in self-administration of SCIG.
Time Frame: Day 2, Day 3.
|
Proportion of participants who successfully trained in self-administration of SCIG expressed as a percentage (completed training/underwent training x 100).
|
Day 2, Day 3.
|
Proportion of participants completing the study.
Time Frame: Day 42
|
Proportion of patients who completed the study expressed as a percentage (finished study/started study x 100).
|
Day 42
|
Infusion nurse's assessment of this participant population's ability to use this treatment modality (Written impression)
Time Frame: Day 42
|
Qualitative measure.
Narrative reflecting the infusion nurse's overall impression of target population's ability to employ SCIG within the parameters defined by the study.
(data is a written narrative.
By definition, this has no units nor is it collected by any instrument (questionnaire, scale parameter ect.) ie.
QUALITATIVE data)
|
Day 42
|
Speed of treatment onset of SCIG.
Time Frame: Day 1
|
The number of days between prescription of SCIG treatment and infusion of first dose.
|
Day 1
|
Speed of treatment onset of IVIG.
Time Frame: Day 1
|
The number of days between prescription of IVIG treatment and infusion of first dose, for any study participant who has received IVIG treatments in the past.
This interval will be determined for all available previous IVIG infusions for each patient.
|
Day 1
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Zaeem A Siddiqi, MD, PhD, University of Alberta
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Immune System Diseases
- Neoplasms
- Autoimmune Diseases of the Nervous System
- Autoimmune Diseases
- Neoplasms by Site
- Neuromuscular Diseases
- Neurodegenerative Diseases
- Nervous System Neoplasms
- Paraneoplastic Syndromes, Nervous System
- Paraneoplastic Syndromes
- Neuromuscular Junction Diseases
- Myasthenia Gravis
- Physiological Effects of Drugs
- Immunologic Factors
- Antibodies
- Immunoglobulins
- Immunoglobulins, Intravenous
- Immunoglobulin G
Other Study ID Numbers
- ZS2013-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myasthenia Gravis
-
Assiut UniversityRecruitingNervous System Diseases | Autoimmune Diseases of the Nervous System | Thymoma | Myasthenia Gravis | Neuromuscular Junction Diseases | Myasthenia Gravis, Generalized | Myasthenia Gravis Crisis | Myasthenia Gravis, Ocular | Myasthenia Gravis, Juvenile Form | Thymus Hyperplasia | Myasthenia Gravis With Exacerbation... and other conditionsEgypt
-
Universiti Putra MalaysiaEnrolling by invitationExperimental MyastheniaChina
-
Universiti Putra MalaysiaCompletedExperimental MyastheniaChina
-
Alexion Pharmaceuticals, Inc.CompletedMyasthenia Gravis | Myasthenia Gravis, Generalized | Myasthenia Gravis, Juvenile FormUnited States, Japan, Netherlands
-
COUR Pharmaceutical Development Company, Inc.Not yet recruitingMyasthenia Gravis | Generalized Myasthenia | AChR Myasthenia Gravis | MuSK MGUnited States
-
Fondation Ophtalmologique Adolphe de RothschildCompleted
-
University of Missouri-ColumbiaUniversity of Kansas Medical CenterRecruitingGeneralized Myasthenia GravisUnited States
-
Fondazione Policlinico Universitario Agostino Gemelli...Recruiting
-
Alexion Pharmaceuticals, Inc.RecruitingGeneralized Myasthenia GravisChina, United States, Spain, United Kingdom, Korea, Republic of, Italy, Germany, Japan, Brazil, France, Netherlands, Taiwan, Turkey, Israel, Poland, Austria, Denmark, Portugal, Canada, Serbia, Argentina, Switzerland
-
Immunovant Sciences GmbHRecruitingGeneralized Myasthenia GravisUnited States, Poland, Romania, Italy, Georgia, Korea, Republic of, Canada, Japan, Hungary, Spain, Serbia, Germany
Clinical Trials on Human normal immunoglobulin G (IgG)
-
Assistance Publique - Hôpitaux de ParisCSL Behring; Association ASLUMARECompleted
-
Assistance Publique - Hôpitaux de ParisInstitut PasteurRecruitingHypersensitivity, Immediate | Peri-operative Injury | Antibody Hypersensitivity | Antibiotic AllergyFrance
-
Technische Universität DresdenGWT-TUD GmbHCompletedPrimary Immunodeficiency (PID) | Secondary Immunodeficiency (SID) | Neurological Autoimmune DiseaseGermany
-
Laboratoire français de Fractionnement et de BiotechnologiesTFS Trial Form SupportCompletedMotor Neuron DiseaseSpain, United Kingdom, Italy, France
-
Omicron PharmaceuticalsCompletedMyocardial Ischemia | Acute Coronary SyndromeLebanon
-
IRCCS Sacro Cuore Don Calabria di NegrarNot yet recruitingStrongyloides Stercoralis InfectionItaly
-
Hansa Biopharma ABCompletedGuillain-Barré Syndrome (GBS)France, Netherlands, United Kingdom
-
Medical University of SilesiaUnknownSevere Acute Respiratory Syndrome | RNA Virus Infections | Respiratory Tract Infections | Covid19 | Corona Virus Infection | Respiratory Tract Disease | Virus DiseasePoland
-
Herlev HospitalRigshospitalet, Denmark; Hvidovre University Hospital; University Hospital Bispebjerg... and other collaboratorsCompleted